FDA Approves Axi-Cel for Large B-cell Lymphoma – Targeted Oncology
|
FDA Approves Axi-Cel for Large B-cell Lymphoma
Targeted Oncology The FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed or refractory large B-cell lymphoma, making the agent the second approved CAR T-cell therapies in the United States. The agent is indicated … |
